Immunogenicity and Tolerability of a SARS-CoV-2 TNX-1800, a Live Recombinant Poxvirus Vaccine Candidate, in Syrian Hamsters and New Zealand White Rabbits
Viruses · 2023
DOI: 10.3390/v15102131 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Mayanka Awasthi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Tonix Pharmaceutical, Frederick, MD 21701, USA. Hauptthemen laut MEDLINE: COVID-19, Poxviridae. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tonix Pharmaceuticals Holding Corp.
Abstract (Originalsprache)
TNX-1800 is a preclinical stage synthetic-derived live attenuated chimeric horsepox virus vaccine engineered to express the SARS-CoV-2 spike (S) gene. The objectives of this study were to assess the safety, tolerability, and immunogenicity of TNX-1800 administration in Syrian golden hamsters and New Zealand white rabbits. Animals were vaccinated at three doses via percutaneous inoculation. The data showed that the single percutaneous administration of three TNX-1800 vaccine dose levels was well tolerated in both hamsters and rabbits. At all dose levels, rabbits were more decerning regarding vaccine site reaction than hamsters. Lastly, no TNX-1800 genomes could be detected at the site of vaccination. Post-vaccination, all animals had anti-SARS-CoV-2 spike protein IgG specific antibody responses. These data demonstrate that TNX-1800 infection was limited, asymptomatic, and cleared by the end of this study, and a single dose was able to generate immune responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tonix Pharmaceutical, Frederick, MD 21701, USA.
- Southern Research, Birmingham, AL 35205, USA.
- Department of Medical Microbiology & Immunology, Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB T6G 2R3, Canada.
- Tonix Pharmaceuticals, Chatham, NJ 07928, USA.
- Tonix Pharmaceuticals, Dartmouth, MA 02745, USA.
ORCID-Profile: Mayanka Awasthi, Ryan S Noyce, Seth Lederman
Förderung
- Tonix Pharmaceuticals Holding Corp
Zitieren
APA
Awasthi, M., Macaluso, A., Goebel, S. J., Luea, E., Noyce, R. S., Nasar, F., Daugherty, B., Bavari, S., & Lederman, S. (2023). Immunogenicity and Tolerability of a SARS-CoV-2 TNX-1800, a Live Recombinant Poxvirus Vaccine Candidate, in Syrian Hamsters and New Zealand White Rabbits. Viruses. https://doi.org/10.3390/v15102131
Vancouver
Awasthi M, Macaluso A, Goebel SJ, Luea E, Noyce RS, Nasar F, et al. Immunogenicity and Tolerability of a SARS-CoV-2 TNX-1800, a Live Recombinant Poxvirus Vaccine Candidate, in Syrian Hamsters and New Zealand White Rabbits. Viruses. 2023. doi:10.3390/v15102131
BibTeX
@article{Awasthi2023,
author = {Awasthi, Mayanka and Macaluso, Anthony and Goebel, Scott J and Luea, Erin and Noyce, Ryan S and Nasar, Farooq and Daugherty, Bruce and Bavari, Sina and Lederman, Seth},
title = {Immunogenicity and Tolerability of a SARS-CoV-2 TNX-1800, a Live Recombinant Poxvirus Vaccine Candidate, in Syrian Hamsters and New Zealand White Rabbits},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15102131}
}
EUVIMED